Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis TranscriptSeeking Alpha · 3 days ago
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis ResultsMarketBeat · 3 days ago
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewsWire · 3 days ago
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)GlobeNewsWire · 3 days ago
Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.Defense World · Oct 16, 2026
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)Defense World · Oct 6, 2026Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.30 | -$0.33 | Miss |
| May 20, 2026 | -$0.29 | -$0.28 | Beat |
| Feb 6, 2026 | -$0.30 | -$0.24 | Beat |
| Nov 10, 2025 | -$0.32 | -$0.20 | Beat |
| Aug 11, 2025 | -$0.25 | -$0.25 | Miss |
| May 29, 2025 | -$0.26 | -$0.29 | Miss |